Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 37

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 37
---
 the occurrence of certain change of control events relating to our company, which also could discourage,
delay or prevent a business combination transaction.

The Company is not subject
to Section 203 of the Delaware General Corporation Law (the “DGCL”). In general, Section 203 may prohibit large
stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a period of
time without the approval of our board of directors. The Company elected to “opt out” of the provisions of Section 203
of the Delaware General Corporation Law (the “DGCL”) in the Third Amended and Restated Certificate of Incorporation.

<div align='center'>9</div>

Transfer Agent and Registrar

The transfer agent and registrar for our common
stock is VStock Transfer, LLC.

Stock Market Listing

Our common stock is listed on The Nasdaq Capital
Market under the symbol “DERM.”

<div align='center'>10

DESCRIPTION OF DEBT SECURITIES</div>

The following description, together with the additional
information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the debt securities that
we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may
offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus
supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the
terms described below, the terms set forth in the prospectus supplement shall control.

We may sell from time to time, in one or more
offerings under this prospectus, debt securities, which may be senior or subordinated. We will issue any such senior debt securities under
a senior indenture that we will enter into with a trustee to be named in the senior indenture. We will issue any such subordinated debt
securities under a subordinated indenture, which we will enter into with a trustee to be named in the subordinated indenture. We use the
term “indentures” to refer to either the senior indenture or the subordinated indenture, as applicable. The indentures will
be qualified under the Trust Indenture Act of 1939, as in effect